



Biotech Daily

SPECIAL SUMMER CATCH-UP EDITION

Sunday, January 19, 2025

The Summer Catch-Up Edition was compiled by Deputy Editor Jamie Miller

- * ENLITIC LOSES DIRECTOR RIICHI YAMADA
- * CONTROL BIONICS SHORTFALL RAISES \$310k: \$250k TO GO
- * VECTUS APPOINTS LINDA WALTERS DIRECTOR
- * PRO MEDICUS SIGNS \$30m DULY HEALTH VISAGE DEAL
- * RHYTHM \$625k FOR GENETIC TECHNOLOGIES GENETYPE TEST
- * BRANDON CUREATOR, AND HEALTH \$18.5m FOR 8 MEDTECH START-UPS
- * MACH7 SIGNS \$4.6m EUNITY, BLACKFORD CONTRACTS
- * POLYNOVO RECORDS 1st \$10m SALES MONTH
- * COMPUMEDICS EXPECTS RECORD H1 SALES ORDERS UP 200% TO \$31m
- * IMUGENE UP-TO \$46m CONVERTIBLE NOTE, WARRANTS
- * ACRUX SHARE PLAN RAISES \$1.3m OF \$2m; TOTAL \$4m
- * MEMPHASYS TOP-UP RAISES \$47.5k; TOTAL \$1.9m
- * AROA: 'MYRIAD COVERS LOWER LIMB WOUNDS IN 30 DAYS'
- * PRESCIENT: FDA OKAYS PHASE II PTX-100 CANCER TRIAL
- * EBR COMPLETES FDA 100-DAY WISE MEETING, APPROVAL ON-TRACK
- * CLINUVEL CANADA REVIEWS SCENESSE FOR EPP FILING
- * IMRICOR FILES NORTHSTAR 3-D MRI MAPPING TO EU
- * AVITA RECELL GO MINI WOUND TREATMENT WINS FDA APPROVAL
- * OSTEOPORE EGM APPROVES \$20m CONVERTIBLE NOTE ISSUE
- * ECHO IQ REQUESTS ECHOSOLV FDA PRE-TRIAL MEETING
- * NYRADA RECEIVES \$1.2m FEDERAL R&D TAX INCENTIVE
- * PRO MEDICUS SIGNS \$15m VISAGE DUKE UNIVERSITY DEAL
- * RADIOPHARM: \$3.2m LANTHEUS RADIO-PHARMACEUTICAL DEAL

- * TELIX FILES TLX250-CDX KIDNEY CANCER TO FDA
- * PROTEOMICS: 'PROMARKER ENDO ACCURATE FOR ENDOMETRIOSIS'
- * DIMERIX DOSES 50% OF PHASE III DMX-200 KIDNEY DISEASE TRIAL
- * IMRICOR: 1st QATAR ICMR EQUIPMENT ORDER
- * AUDEARA TAKES \$297k STURT CAPITAL R&D LOAN
- * TELIX INCREASES M-D DR CHRIS BEHRENBRUCH BASE PAY TO \$799k
- * PROTEOMICS: 'OXIDX IDENTIFIES MUSCLE DAMAGE IN ATHLETES'
- * NYRADA FILES FOR PHASE Ia NYR-BI03 TRIAL ETHICS APPROVAL
- * CARL CHARALAMBOUS BELOW 5% OF HERAMED
- * PHILLIP ASSET DILUTED TO 10.5% OF CYNATA
- * CARDIEX CHAIR NIALL CAIRNS, CEO CRAIG COOPER TAKE 36%
- * REGAL FUNDS TAKES 7.3% OF CARDIEX
- * PETER MULLIN REPLACES UNIVERSAL BIOSENSORS CFO SALESH BALEK
- * ONCOSIL ENROLS 1st ADELAIDE HOSPITAL PANCREATIC CANCER PATIENT
- * BTC COMPLETES CORCYM AUSTRALIA, NZ HEART VALVE DEAL
- * DR CATHY FOLEY ENDS TERM AS AUSTRALIA CHIEF SCIENTIST
- * REGAL DILUTED TO 6% OF CARDIEX
- * IMUGENE DOSES 1st AUSTRALIAN AZER-CEL PATIENT
- * MERCER INVESTMENTS TAKES 5% OF MICROBA
- * IMMUTEP ENROLS PHASE I EFTI, CHEMO LUNG CANCER TRIAL
- * MEMPHASYS, HERANOVA BEGIN CHINA FELIX STUDY
- * PERCHERON: POST-PHASE IIb TRIAL REVIEW, COST CUTS, NEW PROGRAMS
- * EBR PLEADS 'SCHULTZ' TO 31% ASX PRICE QUERY
- * CYCLOPHARM PLEADS 'SCHULTZ' TO ASX 35% PRICE QUERY
- * POWERHOUSE TAKES 5% OF PERCHERON
- * WEHI: 'IRON INFUSION BEATS TABLET FOR ANEMIC PREGNANT WOMEN'
- * 4D MEDICAL: FDA APPROVES IQ-UIP A.I. FIBROSIS DIAGNOSTIC
- * DIMERIX UP-TO \$107m DMX-200 JAPAN FUSO PHARMA LICENCE
- * ARGENT RAISES \$7.3m AT 370% PREMIUM

- * OPYL, X FIRM SIGN TRIALKEY A.I. EXPANSION DEAL
- * PERCHERON BOARD SPILL CALL
- * GREG PETERS, STATEMOOR, XEC TAKE 5% OF PERCHERON
- * ZHENG YANG TAKES 24.5% OF CAMBIUM
- * AVITA EXPECTS REVENUE UP 28% TO \$103m
- * NEXT SCIENCE, FORMER EMPLOYEE LEGAL PROCEEDINGS
- * ISLAND ENROLS 4 OF 10 PHASE IIb ISLA-101 DENGUE FEVER PATIENTS
- * ONCOSIL RECEIVES \$1m FEDERAL R&D TAX INCENTIVE
- * FLOREY DEVELOPS DEMENTIA BRAIN FUNCTION DECLINE TEST
- * SHENASABY INVESTMENTS DILUTED BELOW 5% OF BOTANIX
- * ROPEHAWN INVESTMENTS TAKES 6.1% OF RENERVE
- * AROVELLA RAISES \$20m
- * RADIOPHARM RAISES \$8m, LANTHEUS TAKES 12%
- * VICTORIA \$1.5m FOR WOMEN'S HEALTH RESEARCH
- * IMUGENE RECEIVES \$11.7m FEDERAL R&D TAX INCENTIVE
- * TELIX UP-TO \$372m IMAGINAB ACQUISITION
- * 4D MEDICAL, US DEFENSE CT VQ LUNG PILOT PROGRAM
- * ACTINOGEN: W.H.O GRANTS XANAMEM 'EMESTEDASTAT' NAME
- * PACIFIC EDGE: NOVITAS ENDS US CXBLADDER CANCER TEST COVERAGE
- * LUMOS, MEDPRO US FEBRIDX CONTRACT SALES COVERAGE
- * TELIX UNAUDITED REVENUE UP 56% TO 783m
- * MESOBLAST RAISES \$260m FOR US RYONCIL LAUNCH
- * BIOXYNE 6-MONTH REVENUE \$12.5m; NEW FACTORY
- * ATOMO \$5.44m NEWFOUNDLAND TEST DISTRIBUTOR DEAL
- * VAXXAS WINS BARDA \$3.2m COVID PATCH VACCINE
- * GEORGE MEDICINES, BAUSCH: CANADA, LATIN AMERICA GMRX2 DEAL
- * IMMURON FILES PHASE II TRAVELAN E COLI DATA TO FDA
- * OSTEOPORE IMPLANTS WIN SINGAPORE SUBSIDY APPROVAL
- * FIREBRICK WINS SINGAPORE NASODINE PATENT INFRINGEMENT CASE

- * VITURA STOPS FUNDING CDA CLINICS TGA LEGAL DEFENCE
- * VISIONEERING EGM 94% BACK ASX DELISTING
- * NANOSONICS APPOINTS GERARD DALBOSCO DIRECTOR
- * COMPUMEDICS RECORD \$32.8m H1 SALES ORDERS
- * ORTHOCELL H1 REVENUE UP 29% to \$4.24m
- * NEUREN FILES EU TROFINETIDE MARKETING SUBMISSION
- * IMMURON, MONASH UNI TO WORK ON ANTI-MICROBIAL RESISTANCE
- * GENETIC TECHNOLOGIES TO SELL EASY DNA, AFFINITY DNA
- * INSIGNIA REDUCES TO 9.3% OF BOTANIX
- * UNIVERSAL BIOSENSORS APPOINTS CEO, CFO EXECUTIVE DIRECTORS
- * MICRO-X FORMER CHAIR PATRICK O'BRIEN REPLACES CHAIR DAVID KNOX
- * ONCOSIL APPOINTS LEL SMITS DIRECTOR
- * ANTEOTECH APPOINTS MERRILL GRAY DIRECTOR
- * PRO MEDICUS WINS \$33m KENTUCKY UNI VISAGE CONTRACT
- * VISIONEERING: 'NATURALVUE COMPARABLE TO FDA MYOPIA THERAPY'
- * DIMERIX ENROLS 1st PHASE III DMX-200 FSGS CHILD PATIENT
- * ACRUX TO SELL 90g DAPSONE FOR ACNE IN US
- * USCOM TAKES \$1m CHAIR PROF ROBERT PHILLIPS LOAN
- * ARTRYA PLEADS 'SCHULTZ' TO ASX 49% PRICE QUERY
- * CONVERGENCE MEDICAL RAISES \$5m FOR SURGICAL ROBOT
- * JENCAY TAKES 5.1% OF MEDADVISOR
- * TELIX WINS EU ILLUCIX PROSTATE CANCER APPROVAL
- * POLYNOVO UNAUDITED H1 REVENUE UP 23% TO \$60m
- * SDI UNAUDITED H1 REVENUE DOWN 1.4% TO \$51.5m
- * CLINUVEL: DILIGENS SALUD ARGENTINA SCENESSE DISTRIBUTOR
- * FDA CLINICAL HOLD FOR NEURIZON NUZ-001 ALS APPLICATION
- * IMMURON UNAUDITED H1 TRAVELAN SALES UP 70% TO \$4m
- * POWERHOUSE TAKES 7.4% OF PERCHERON
- * PERENNIAL TAKES 13% OF MEDADVISOR

The following articles appear in date order

Friday December 20, 2024

ENLITIC LOSES DIRECTOR RIICHI YAMADA

[ENLITIC](#)

Enlitic says non-executive director Riichi Yamada has resigned, effective from December 31, 2024, and it “will not seek a replacement director at this time”.

CONTROL BIONICS SHORTFALL RAISES \$310k: \$250k TO GO

[CONTROL BIONICS](#)

Control Bionics says it raised \$310,000 at 7.0 cents a share of the \$560,000 shortfall from its one-for-seven rights issue which raised \$1.53 million (BD: Oct 17, 2024).

VECTUS APPOINTS LINDA WALTERS DIRECTOR

[VECTUS BIOSYSTEMS](#)

Vectus says it has appointed Linda Walters as a non-executive director, effective from December 20, 2024.

Monday December 23, 2024

PRO MEDICUS SIGNS \$30m DULY HEALTH VISAGE DEAL

[PRO MEDICUS](#)

Pro Medicus says it has a \$30 million, seven-year deal to supply its Visage7 patient archiving and communication system to Chicago’s Duly Health and Care.

RHYTHM \$625k FOR GENETIC TECHNOLOGIES GENETYPE TEST

[RHYTHM BIOSCIENCES, GENETIC TECHNOLOGIES](#)

Rhythm says it will pay about \$625,000 in cash to acquire Genetic Technologies’ Genetype risk assessment test for cancer and other diseases.

Rhythm said the “existing Genetype business customers and stakeholders present a valuable opportunity to accelerate Colostat development, validation and market entry”. The company said it would work with Genetic Technologies’ administrators to ensure a “smooth integration of the Genetype business post-completion” (BD: Dec 16, 2024).

BRANDON CUREATOR, AND HEALTH \$18.5m FOR 8 MEDTECH START-UPS

[BRANDON CAPITAL, AUSTRALIA’S NATIONAL DIGITAL HEALTH INITIATIVE](#)

Brandon Capital says it Biocatalyst’s Cureator with AND Health will provide \$18.5 million for eight medical device, diagnostic and technologies start-ups.

A media release from Brandon Cureator said the funds, from the Federal Government’s Medical Research Future Fund, would be used to commercialize pre-clinical and clinical medical research, with a list of recipients at: <https://bit.ly/49NQYPf>.

MACH7 SIGNS \$4.6m EUNITY, BLACKFORD CONTRACTS

[MACH7 TECHNOLOGIES](#)

Mach7 says it has a \$2.5 million deal to supply its Eunity viewer and patient archiving and communication system to four Adventist Health hospitals.

Mach7 said it had an additional \$2.1 million deal for its Blackford A.I., or artificial intelligence, platform with the Veterans Health Administration (BD: Jul 3, 2023).

POLYNOVO RECORDS 1st \$10m SALES MONTH

[POLYNOVO](#)

Polynovo says it has record unaudited monthly sales of its wound repair products for November 2024 of \$10.1 million, the first monthly sales result of more than \$10 million.

COMPUMEDICS EXPECTS RECORD H1 SALES ORDERS UP 200% TO \$31m

[COMPUMEDICS](#)

Compumedics says it expects record sales orders for its Somfit home sleep test and other products for the six months to December 31, 2024 to be up more than 200 percent to \$31 million.

IMUGENE UP-TO \$46m CONVERTIBLE NOTE, WARRANTS

[IMUGENE](#)

Imugene says it expects to raise \$20 million in interest free convertible notes and \$26 million in warrants to Philadelphia, Pennsylvania's CVI Investments for clinical trials. Imugene said the deal was subject to shareholder approval, the notes were convertible at a 25 percent premium to its closing price on December 20, 2024, or 4.75 cents and the warrants were exercisable at 4.94 cents each within five years.

ACRUX SHARE PLAN RAISES \$1.3m OF \$2m; TOTAL \$4m

[ACRUX](#)

Acrux says it has raised \$1.34 million of a hoped-for \$2 million in a share plan at 3.5 cents a share, taking the total raised to \$4.0 million (BD: Dec 5, 2024).

MEMPHASYS TOP-UP RAISES \$47.5k; TOTAL \$1.9m

[MEMPHASYS](#)

Memphasys says it has raised \$47,500 in a top-up offer, in addition to the \$1,857,000 it raised at 0.6 cents a share in its placement and share plan (BD: Nov 5, 2024).

AROA: 'MYRIAD COVERS LOWER LIMB WOUNDS IN 30 DAYS'

[AROA BIOSURGERY](#)

Aroa says a 120-patient study shows its Myriad Matrix and Myriad Morcells for lower limb reconstructions led to lower limb coverage and fill in 30 days with one application. Aroa said the study showed its products led to savings of up-to 195 percent compared to other dermal matrices for lower extremity reconstruction: <https://bit.ly/405R3uj>.

PRESCIENT: FDA OKAYS PHASE II PTX-100 CANCER TRIAL

[PRESCIENT THERAPEUTICS](#)

Prescient says it has US Food and Drug Administration investigational new drug application approval for its phase II trial of PTX-100 for T-cell lymphomas.

EBR COMPLETES FDA 100-DAY WISE MEETING, APPROVAL ON-TRACK

[EBR SYSTEMS](#)

EBR says it completed its 100-day meeting with the US Food and Drug Administration for its Wise pacemaker and "approval timing remains on track" (BD: Dec 19, 2024).

CLINUVEL CANADA REVIEWS SCENESSE FOR EPP FILING

[CLINUVEL PHARMACEUTICALS](#)

Clinuvel says its new drug submission for Scenesse, or afamelanotide, for photo-protective protoporphyria (EPP) has been accepted for review by Health Canada.

IMRICOR FILES NORTHSTAR 3-D MRI MAPPING TO EU

[IMRICOR MEDICAL SYSTEMS](#)

Imricor says it has filed its Northstar 3-dimensional mapping system with magnetic resonance imaging (MRI) for Conformité Européene certification in Europe.

Tuesday December 24, 2024

AVITA RECELL GO MINI WOUND TREATMENT WINS FDA APPROVAL

[AVITA MEDICAL](#)

Avita says it has US Food and Drug Administration approval for Recell Go Mini disposable spray-on-skin cartridges for smaller full-thickness wounds.

OSTEOPORE EGM APPROVES \$20m CONVERTIBLE NOTE ISSUE

[OSTEOPORE](#)

Osteopore says it has shareholder approval to issue \$20 million in convertible notes at four percent interest to the Cayman Island's Advance Opportunities Fund.

ECHO IQ REQUESTS ECHOSOLV FDA PRE-TRIAL MEETING

[ECHO IQ](#)

Echo IQ says it has requested a meeting with the US Food and Drug Administration to approve the design of a validation trial of its Echosolv heart failure screening software.

NYRADA RECEIVES \$1.2m FEDERAL R&D TAX INCENTIVE

[NYRADA](#)

Nyrada says it has received \$1,235,480 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.

Wednesday, December 25, Thursday December 26, 2024

ASX closed for Christmas, Boxing Day.

Friday December 27, 2024

No announcements.

Monday December 30, 2024

PRO MEDICUS SIGNS \$15m VISAGE DUKE UNIVERSITY DEAL

[PRO MEDICUS](#)

Pro Medicus says it has a \$15 million, five-year deal to supply its Visage 7 imaging and archive management software to Durham, North Carolina's Duke University.

RADIOPHARM: \$3.2m LANTHEUS RADIO-PHARMACEUTICAL DEAL

[RADIOPHARM THERANOSTICS](#)

Radiopharm says it may receive up-to \$US2 million (\$A3.2 million) under an agreement to conduct clinical research for Lantheus in Australia (BD: Aug 5, 2024).

TELIX FILES TLX250-CDX KIDNEY CANCER TO FDA

[TELIX PHARMACEUTICALS](#)

Telix says it has filed a biologics licence application for TLX250-CDx positron emission tomography for imaging kidney cancer to the US Food and Drug Administration.

PROTEOMICS: 'PROMARKER ENDO ACCURATE FOR ENDOMETRIOSIS'

[PROTEOMICS INTERNATIONAL LABORATORIES](#)

Proteomics says a study of 805 plasma samples shows its Promarker Endo blood test "identifies all stages of endometriosis with high accuracy".

DIMERIX DOSES 50% OF PHASE III DMX-200 KIDNEY DISEASE TRIAL

[DIMERIX](#)

Dimerix says it has dosed half, or 144 patients, in its phase III trial of DMX-200 for focal segmental glomerulo-sclerosis, with all patients expected to be dosed in 2025.

IMRICOR: 1st QATAR ICMR EQUIPMENT ORDER

[IMRICOR MEDICAL SYSTEMS](#)

Imricor says it has its first order from Qatar for equipment and consumables relating to its interventional cardiac magnetic resonance imaging (ICMR) laboratory products. Imricor said the products included its vision atrial flutter kits, ablation cables, diagnostic cables, dispersive electrodes and recorder/stimulator.

AUDEARA TAKES \$297k STURT CAPITAL R&D LOAN

[AUDEARA](#)

Audeara says it has a Sturt Capital \$296,902 loan at 1.33 percent monthly interest against an expected Federal Research and Development Tax Incentive.

TELIX INCREASES M-D DR CHRIS BEHRENBRUCH BASE PAY TO \$799k

[TELIX PHARMACEUTICALS](#)

Telix says it has increased managing-director Dr Chris Behrenbruch's base pay to \$799,902 a year to reflect "the achievement of key business inflection points". In April, Telix said Dr Behrenbruch's yearly pay was \$570,780 (BD: Apr 22, 2024).

Tuesday December 31, 2024

PROTEOMICS: 'OXIDX IDENTIFIES MUSCLE DAMAGE IN ATHLETES'

[PROTEOMICS INTERNATIONAL LABORATORIES](#)

Proteomics says its Oxidx finger-prick, blood test for oxidative stress "can identify and assess recovery from exercise-induced muscle damage in elite marathon runners".

NYRADA FILES FOR PHASE Ia NYR-BI03 TRIAL ETHICS APPROVAL

[NYRADA](#)

Nyrada says it has applied for ethics approval for its first-in-human, 40-participant, phase Ia clinical trial of NYR-BI03 for stroke and brain injury.

CARL CHARALAMBOUS BELOW 5% OF HERAMED

[HERAMED](#)

Brisbane's Carl Charalambous says he has reduced and been diluted below five percent in Heramed, selling 30,051,173 shares for \$272,141, or 0.9 cents a share.

PHILLIP ASSET DILUTED TO 10.5% OF CYNATA

[CYNATA THERAPEUTICS](#)

Melbourne's Phillip Asset Management Ltd says its 23,588,040 share-holding in Cynata was diluted on December 16, 2024 from 13.13 percent to 10.47 percent.

CARDIEX CHAIR NIALL CAIRNS, CEO CRAIG COOPER TAKE 36%

[CARDIEX](#)

Cardiex chair Niall Cairns and chief executive officer Craig Cooper say they increased their shareholding from 68,689,830 shares (23.35%) to 145,689,830 shares (35.95%).

REGAL FUNDS TAKES 7.3% OF CARDIEX

[CARDIEX](#)

The Sydney-based Regal Funds Management says it has become a substantial shareholder in Cardiex with 24,132,898 shares, or 7.31 percent.

PETER MULLIN REPLACES UNIVERSAL BIOSENSORS CFO SALESH BALEK

[UNIVERSAL BIOSENSORS](#)

Universal Biosensors says it has appointed Peter Mullin as chief financial officer, replacing Salesh Balek who continues as company secretary and corporate advisor.

ONCOSIL ENROLS 1st ADELAIDE HOSPITAL PANCREATIC CANCER PATIENT

[ONCOSIL MEDICAL](#)

Oncosil says it has enrolled the first patient at Royal Adelaide Hospital in its trial of its pancreatic cancer device with chemotherapy, taking the total enrolled to 49 patients.

Wednesday January 1, 2025

ASX closed for New Year's Day.

Thursday January 2, 2025

BTC COMPLETES CORCYM AUSTRALIA, NZ HEART VALVE DEAL

[BTC HEALTH](#)

BTC says it has completed its agreement to run the London-based Corcym's Australia and New Zealand operations, effective from January 1, 2025 (BD: Dec 9, 2024)

DR CATHY FOLEY ENDS TERM AS AUSTRALIA CHIEF SCIENTIST

[FEDERAL GOVERNMENT](#)

The Federal Government says Dr Cathy Foley ended her tenure as Australia's chief scientist, effective from December 31, 2024, with a replacement to be announced.

Friday January 3, 2025

REGAL DILUTED TO 6% OF CARDIEX

[CARDIEX](#)

Sydney's Regal Funds says its 24,132,898 share-holding in Cardiex has been diluted from 7.31 percent to 5.96 percent, due to a capital raising on December 30, 2024.

IMUGENE DOSES 1st AUSTRALIAN AZER-CEL PATIENT

[IMUGENE](#)

Imugene says it has dosed the first Australian patient in its up-to 129-patient, phase Ib, trial of 'azer-cel' chimeric antigen receptor (Car) T-cells for B-cell lymphoma.

MERCER INVESTMENTS TAKES 5% OF MICROBA

[MICROBA LIFE SCIENCES](#)

Melbourne's Mercer Investments Australia says it has become a substantial shareholder in Microba with 22,540,245 shares, or 5.033 percent.

Monday January 6, 2025

IMMUTEP ENROLS PHASE I EFTI, CHEMO LUNG CANCER TRIAL

[IMMUTEP](#)

Immutep says it has enrolled its 50-patient, phase I trial of efitlagimod alpha, or efiti, with double chemotherapy for non-small cell lung cancer, with data expected "in 2025".

MEMPHASYS, HERANOVA BEGIN CHINA FELIX STUDY

[MEMPHASYS](#)

Memphasys says with Heranova Lifesciences it has begun its 50-case study of Felix for in-vitro fertilization at a hospital in Chengdu, China (BD: Dec 12, 2024).

PERCHERON: POST-PHASE IIb TRIAL REVIEW, COST CUTS, NEW PROGRAMS

[PERCHERON THERAPEUTICS \(FORMERLY ANTISENSE THERAPEUTICS\)](#)

Percheron says after "negative" phase IIb trial results it will conduct a review, reduce its expenditure and seek to add programs to its pipeline (BD: Dec 18, 2024).

EBR PLEADS 'SCHULTZ' TO 31% ASX PRICE QUERY

[EBR SYSTEMS](#)

ERB has told the ASX that it is not aware of any information it has not announced, which, if known, could explain a 30.9 percent increase in its share price.

CYCLOPHARM PLEADS 'SCHULTZ' TO ASX 35% PRICE QUERY

[CYCLOPHARM](#)

Cyclopharm has told the ASX that it is not aware of any information which, if known, could explain a 35.15 percent increase in its share price.

POWERHOUSE TAKES 5% OF PERCHERON

[PERCHERON THERAPEUTICS \(FORMERLY ANTISENSE THERAPEUTICS\)](#)

Brisbane's Powerhouse Ventures Ltd says it has become a substantial shareholder in Percheron with 55,000,000 shares, or 5.058 percent.

Tuesday January 7, 2025

4D MEDICAL: FDA APPROVES IQ-UIP A.I. FIBROSIS DIAGNOSTIC

[4D MEDICAL](#)

4D Medical says it has US Food and Drug Administration approval for its IQ-usual interstitial pneumonia (UIP) artificial intelligence (A.I.) diagnostic for pulmonary fibrosis.

WEHI: 'IRON INFUSION BEATS TABLET FOR ANAEMIC PREGNANT WOMEN' [WALTER AND ELIZA HALL MEDICAL RESEARCH INSTITUTE](#)

The Walter and Eliza Hall Medical Research Institute says it has shown a single iron infusion outperforms iron tablets in reducing anaemia in pregnant women.

WEHI said a third-trimester infusion protected women's iron stores, with a 46.7 percent anaemia prevalence compared to 62.7 percent for iron tablets, at the time of delivery. The Institute said the study, titled 'Ferric carboxymaltose for anaemia in late pregnancy' was published in Nature Medicine and available at: <https://bit.ly/4gZL7sW>.

DIMERIX UP-TO \$107m DMX-200 JAPAN FUSO PHARMA LICENCE [DIMERIX](#)

Dimerix says it will receive up-to \$107 million to licence DMX-200 for focal segmental glomerulosclerosis (FSGS) in Japan to Osaka's Fuso Pharmaceutical Industries.

Dimerix said it would receive \$3.1 million in an up-front payment as well as \$4.1 million on first development milestone, expected by April 2025 and \$100 million in further potential development and sales milestones.

ARGENT RAISES \$7.3m AT 370% PREMIUM [ARGENT BIOPHARMA \(FORMERLY MEDICAL GRADE CANNABIS PHARMA\)](#)

Argent says it has raised \$US4,500,000 (\$A7,300,000) through the issue of shares at 40 US cents (64 Australian cents) each, a 370 percent premium to its 15-day volume-weighted average price, with one option for every two shares acquired exercisable at 55 US cents (88 Australian cents) each within three years.

OPYL, X FIRM SIGN TRIALKEY A.I. EXPANSION DEAL [OPYL](#)

Opyl says London's X Firm will commercialize its Trialkey artificial intelligence (A.I.)-based software for clinical trials in Europe, the Middle East, Africa and North America.

PERCHERON BOARD SPILL CALL [PERCHERON THERAPEUTICS \(FORMERLY ANTISENSE THERAPEUTICS\)](#)

Percheron says it has received notices from shareholders calling for a general meeting to vote for the replacement of directors Dr Charmaine Gittleson and Dr James Garner. Percheron said the shareholders (see below) included Gregory Peters, Dale Reed and others and had proposed to elect Mr Peters and Gennadi Koutchin as directors.

GREG PETERS, STATEMOOR, XEC TAKE 5% OF PERCHERON [PERCHERON THERAPEUTICS \(FORMERLY ANTISENSE THERAPEUTICS\)](#)

Gregory Peters says with related parties he has become a substantial shareholder in Percheron with 55,675,081 shares, or 5.1 percent (see above).

The Melbourne-based Mr Peters said that he held more than five percent with the combined interest of Dale Reed, Robert Moses, David Kinley, Statemoor, Xcelerate Nominees and XEC Partners.

ZHENG YANG TAKES 24.5% OF CAMBIUM [CAMBIUM BIO \(FORMERLY REGENEUS\)](#)

Taipei, Taiwan's Zheng Yang Biomedical Technology says it has increased its holding in Cambium from 99,677,861 shares (13.01%) to 292,694,170 shares (24.53%).

Wednesday January 8, 2024

AVITA EXPECTS REVENUE UP 28% TO \$103m

[AVITA MEDICAL](#)

Avita says it expects revenue for the year to December 31, 2024 to be up 28.2 percent to about \$US64.3 million (\$A103.4 million), compared to \$US50.1 million in the previous period (BD: Feb 23, 2024).

NEXT SCIENCE, FORMER EMPLOYEE LEGAL PROCEEDINGS

[NEXT SCIENCE](#)

Next Science says a former employee has filed a lawsuit in a Florida court “alleging breaches of fiduciary duties and mismanagement against several employees”. Next Science said the complaint was filed in the Fourth Judicial Circuit Court in Florida and alleged its Xbio was not approved by the US Food and Drug Administration as a biofilm eradication process and that it “did not take adequate measures to address safety concerns about the use of ... Xperience in breast implant procedures”. The company said the complaint was brought by former head of wound care sales Michael Morello, and that it was currently pursuing a non-compete action against Mr Morello and several former employees for breaching post-employment restraints.

ISLAND ENROLS 4 OF 10 PHASE IIb ISLA-101 DENGUE FEVER PATIENTS

[ISLAND PHARMACEUTICALS](#)

Island says it has enrolled the first four patients in its up-to 10-patient, phase IIb trial of ISLA-101 for dengue fever, with results expected by “around April 2025”.

ONCOSIL RECEIVES \$1m FEDERAL R&D TAX INCENTIVE

[ONCOSIL MEDICAL](#)

Oncosil says it has received \$1,050,896 from the Australian Taxation Office under the Federal Government’s Research and Development Tax Incentive program.

Thursday January 9, 2025

FLOREY DEVELOPS DEMENTIA BRAIN FUNCTION DECLINE TEST

[THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH](#)

Florey Institute says it has developed a statistical model using a neuro-psychological test to predict brain function decline and dementia in Alzheimer’s disease. The Institute said the research, titled ‘Development and Validation of a Tool to Predict Onset of Mild Cognitive Impairment and Alzheimer Dementia’ was published on JAMA Network and available at: <https://bit.ly/420xftM>.

SHENASABY INVESTMENTS DILUTED BELOW 5% OF BOTANIX

[BOTANIX PHARMACEUTICALS](#)

Perth’s Shenasy Investments Pty Ltd says its 74,586,791 share-holding in Botanix has been diluted in a placement below the five percent substantial threshold.

ROPEHAWN INVESTMENTS TAKES 6.1% OF RENERVE

[RENERVE](#)

Melbourne’s Ropehawn Investments Pty Ltd says it has become a substantial shareholder in Renerve with 8,617,123 shares, or 6.08 percent.

Friday January 10, 2025

AROVELLA RAISES \$20m

[AROVELLA THERAPEUTICS](#)

Arovella says it has raised \$20 million at 17 cents a share, a 2.9 percent discount to its last closing price, in a placement to investors including Pengana Capital.

RADIOPHARM RAISES \$8m, LANTHEUS TAKES 12%

[RADIOPHARM THERANOSTICS](#)

Radiopharm says it has raised \$US5.0 million (\$A8.0 million) in a placement at six cents a share, a 150 percent premium to its last closing price, to Lantheus Holdings. A Radiopharm email said that Lantheus held 12.16 percent of the company.

VICTORIA \$1.5m FOR WOMEN'S HEALTH RESEARCH

[VICTORIA GOVERNMENT](#)

The Victoria Government says it has provided \$1.5 million for women's health research, with recipients to receive \$50,000 to \$150,000, each.

A media release from the Government said research areas included sexual and reproductive health, cardiovascular health, oncology, orthopaedics and chronic pain.

IMUGENE RECEIVES \$11.7m FEDERAL R&D TAX INCENTIVE

[IMUGENE](#)

Imugene says it has received \$11,689,963 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.

Monday January 13, 2025

TELIX UP-TO \$372m IMAGINAB ACQUISITION

[TELIX PHARMACEUTICALS](#)

Telix says it will buy the antibody engineering company Imaginab Inc for \$US45 million (\$A73 million) up-front and up-to \$US185 million (\$A299 million) in milestones.

Telix said the Los Angeles-based Imaginab Inc had a pipeline of "early-stage drug candidates against high-value targets including DLL3 and integrin alpha-v beta-6 ...[which] fit synergistically with Telix's therapeutics pipeline".

4D MEDICAL, US DEFENSE CT VQ LUNG PILOT PROGRAM

[4D MEDICAL](#)

4D Medical says with the US Department of Defense it will hold an 80-participant study of its computed tomography ventilation-perfusion (CT VQ) technology for lung health.

ACTINOGEN: W.H.O GRANTS XANAMEM 'EMESTEDASTAT' NAME

[ACTINOGEN MEDICAL](#)

Actinogen says the World Health Organisation has granted its Xanamem once-daily oral molecule the generic name "emestedastat".

PACIFIC EDGE: NOVITAS ENDS US CXBLADDER CANCER TEST COVERAGE

[PACIFIC EDGE](#)

Pacific Edge says its US Medicare administrative contractor Novitas will cease reimbursing its Cxbladder urine tests for bladder cancer from February 23, 2025.

LUMOS, MEDPRO US FEBRIDX CONTRACT SALES COVERAGE

[LUMOS DIAGNOSTICS](#)

Lumos says the Denver, Colorado-based Medpro Associates will provide national contract sales coverage for its Febridx point-of-care blood test for infections.

Tuesday January 14, 2025

TELIX UNAUDITED REVENUE UP 56% TO 783m

[TELIX PHARMACEUTICALS](#)

Telix says unaudited revenue for the year to December 31, 2024 has exceeded guidance, up 55.8 percent to \$783 million, compared to \$502.5 million the prior year. Last year, Telix said revenue from sales of its Illucix test for imaging prostate cancer for the year to December 31, 2023 was up 213.9 percent to \$502,547,000, with a maiden profit of \$5,211,000 (BD: Feb 23, 2024).

MESOBLAST RAISES \$260m FOR US RYONCIL LAUNCH

[MESOBLAST](#)

Mesoblast says it has raised \$260 million at \$2.50 a share in a placement to fund the US commercial launch of Ryoncil for graft-versus-host disease in children.

BIOXYNE 6-MONTH REVENUE \$12.5m; NEW FACTORY

[BIOXYNE](#)

Bioxyne says revenue for the six months to December 31, 2024 was about \$12.5 million and it expects to commission a factory doubling manufacturing this month.

ATOMO \$5.44m NEWFOUNDLAND TEST DISTRIBUTOR DEAL

[ATOMO DIAGNOSTICS](#)

Atomo says it has signed a \$5.44 million, five-year deal for London's Newfoundland Diagnostics to supply its HIV self-test in the UK, Europe and Colombia.

VAXXAS WINS BARDA \$3.2m COVID PATCH VACCINE

[VAXXAS PTY LTD](#)

Vaxxas says it has \$3.2 million US Biomedical Advanced Research and Development Authority (Barda) grant to develop its skin patch messenger RNA vaccine for Covid-19.

GEORGE MEDICINES, BAUSCH: CANADA, LATIN AMERICA GMRX2 DEAL

[GEORGE MEDICINES, BRANDON CAPITAL](#)

George Medicines says it has licenced its GMRx2 for hypertension in Canada, Mexico, Columbia and Central America to the Montreal, Quebec's Bausch Health.

A spokesperson for the Brandon Capital company George Medicines told Biotech Daily that the terms of the agreement were "commercial in confidence".

IMMURON FILES PHASE II TRAVELAN E COLI DATA TO FDA

[IMMURON](#)

Immuron says it has filed data from its phase II study of Travelan for entero-toxigenic Escherichia coli to the US Food and Drug Administration to proceed to phase III trials. Immuron said the data showed Travelan reduced the number of colony-forming units in the stools of subjects (p = 0.0121) "indicating faster clearance of the challenge strain from the [gastro-intestinal tract]" and led to "more stable gastro-intestinal microbiota".

OSTEOPORE IMPLANTS WIN SINGAPORE SUBSIDY APPROVAL

[OSTEOPORE](#)

Osteopore says its cranio-maxillo-facial and oculo-plastic implants for bone healing have been added to the Singapore Ministry of Health's Implant Subsidy List. Osteopore did not disclose the subsidy or the cost of its implants.

FIREBRICK WINS SINGAPORE NASODINE PATENT INFRINGEMENT CASE

[FIREBRICK PHARMA](#)

Firebrick says it has successfully removed a competitor product to its Nasodine nasal spray for the common cold in Singapore for infringement of its core patent.

VITURA STOPS FUNDING CDA CLINICS TGA LEGAL DEFENCE

[VITURA HEALTH \(FORMERLY CRONOS AUSTRALIA\)](#)

Vitura says it has "discontinued funding the defence of CDA Clinics Qld" in the court proceedings brought against it by the Australia Therapeutic Goods Administration. In 2023, the TGA said it began proceedings against Vitura's CDA Clinics Qld Pty Ltd for the alleged unlawful advertising of cannabidiol (CBD) (BD: Dec 5, 2023).

VISIONEERING EGM 94% BACK ASX DELISTING

[VISIONEERING TECHNOLOGIES](#)

Visioneering says its extraordinary general meeting has approved the scheme to delist from the ASX with 94.1 percent in support.

NANOSONICS APPOINTS GERARD DALBOSCO DIRECTOR

[NANOSONICS](#)

Nanosonics says it has appointed Medibank Private director Gerard Dalbosco as an independent non-executive director, effective from January 14, 2025.

Wednesday January 15, 2025

COMPUMEDICS RECORD \$32.8m H1 SALES ORDERS

[COMPUMEDICS](#)

Compumedics says it has record sales orders for its sleep and Neuroscan businesses, up 55 percent to \$32.8 million for the six months to December 31, 2024.

ORTHOCELL H1 REVENUE UP 29% to \$4.24m

[ORTHOCELL](#)

Orthocell says revenue from sales of its Remplir and Striate bone repair implants for the six months to December 31, 2024 was up 29.3 percent to a record \$4.24 million.

NEUREN FILES EU TROFINETIDE MARKETING SUBMISSION

[NEUREN PHARMACEUTICALS](#)

Neuren says partner Acadia Pharmaceuticals has applied to the European Medicines Agency for marketing authorization for trofenitide as a treatment of Rett syndrome.

IMMURON, MONASH UNI TO WORK ON ANTI-MICROBIAL RESISTANCE

[IMMURON](#)

Immuron says with Melbourne's Monash University it will develop therapeutic drugs targeting anti-microbial resistant pathogens.

GENETIC TECHNOLOGIES TO SELL EASY DNA, AFFINITY DNA

[GENETIC TECHNOLOGIES](#)

Genetic Technologies administrators says they will sell its direct-to-consumer businesses including Easy DNA and Affinity DNA, with the sale expected to be completed by January 20, 2025.

INSIGNIA REDUCES TO 9.3% OF BOTANIX

[BOTANIX PHARMACEUTICALS](#)

Insignia Financial Ltd says it has reduced its substantial shareholding in Botanix from 187,150,760 shares (10.34%) to 170,091,225 shares (9.32%).

UNIVERSAL BIOSENSORS APPOINTS CEO, CFO EXECUTIVE DIRECTORS

[UNIVERSAL BIOSENSORS](#)

Universal Biosensors says it has appointed chief executive officer John Sharman and chief financial officer Peter Mullin executive directors, effective from January 15, 2025.

MICRO-X FORMER CHAIR PATRICK O'BRIEN REPLACES CHAIR DAVID KNOX

[MICRO-X](#)

Micro-X says director and former chair Patrick O'Brien has been reappointed as its chair following the retirement of David Knox, effective immediately.

ONCOSIL APPOINTS LEL SMITS DIRECTOR

[ONCOSIL MEDICAL](#)

Oncosil says it has appointed Lel Smits as a non-executive director, effective immediately.

ANTEOTECH APPOINTS MERRILL GRAY DIRECTOR

[ANTEOTECH](#)

Anteotech says it has appointed the Europe-based Merrill Gray as a non-executive director, effective from January 31, 2025.

Thursday January 16, 2025

PRO MEDICUS WINS \$33m KENTUCKY UNI VISAGE CONTRACT

[PRO MEDICUS](#)

Pro Medicus says it has a \$33 million, nine-year deal to supply its Visage picture archiving and communication system to Lexington's University of Kentucky.

VISIONEERING: 'NATURALVUE COMPARABLE TO FDA MYOPIA THERAPY'

[VISIONEERING TECHNOLOGIES](#)

Visioneering says two-year study of Naturalvue contact lenses in 145 children with myopia shows Naturalvue was comparable to "the only FDA-approved therapy". Visioneering said the data showed myopia progression control in both refractive error and axial length "consistent with the two-year values achieved" by the comparator.

DIMERIX ENROLS 1st PHASE III DMX-200 FSGS CHILD PATIENT

[DIMERIX](#)

Dimerix says it has recruited the first child in its 286-patient, phase III trial of DMX-200 for focal segmental glomerulo-sclerosis (FSGS) in Manchester, England.

ACRUX TO SELL 90g DAPSONE FOR ACNE IN US

[ACRUX](#)

Acrux says its partner Trupharma has launched a “90-gram pack size” of Dapsone five percent gel in the US as a topical treatment for acne vulgaris.

USCOM TAKES \$1m CHAIR PROF ROBERT PHILLIPS LOAN

[USCOM](#)

Uscom says it has a \$US635,000 (\$A1,021,000) loan from chair Prof Robert Phillips for working capital, at eight percent interest, repayable monthly, by June 30, 2025.

ARTRYA PLEADS ‘SCHULTZ’ TO ASX 49% PRICE QUERY

[ARTRYA](#)

Artrya has told the ASX that it is not aware of any information it has not announced which, if known, could explain the 48.6 percent increase in its share price.

CONVERGENCE MEDICAL RAISES \$5m FOR SURGICAL ROBOT

[CONVERGENCE MEDICAL PTY LTD](#)

Brisbane’s Convergence Medical says it has raised \$5 million in a series A funding round to commercialize its V01 surgical robot for arthroscopic operations. Convergence Medical said its founding chief executive officer was Audeara founder Dr Chris Jeffery and that its V01 robot had US Food and Drug Administration breakthrough device status.

JENCAY CAPITAL TAKES 5.1% OF MEDADVISOR

[MEDADVISOR](#)

Sydney’s Jencay Capital Pty Ltd says it has become a substantial shareholder in Medadvisor with 28,187,111 shares, or 5.11 percent.

Friday January 17, 2025

TELIX WINS EU ILLUCIX PROSTATE CANCER APPROVAL

[TELIX PHARMACEUTICALS](#)

Telix says it has marketing approval for its positron emission tomography imaging agent Illucix for prostate cancer in Europe.

Telix said the “significant milestone” would be followed by national authorization for commercial launch of Illucix in 18 countries, including Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland, France, Greece, Ireland, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Slovakia, Spain and Sweden.

POLYNOVO UNAUDITED H1 REVENUE UP 23% TO \$60m

[POLYNOVO](#)

Polynovo says unaudited revenue for the six months to December 31, 2024 was up 22.8 percent to \$59.9 million, compared to the previous corresponding period.

SDI UNAUDITED H1 REVENUE DOWN 1.4% TO \$51.5m

[SDI \(FORMERLY SOUTHERN DENTAL INDUSTRIES\)](#)

SDI says unaudited revenue for the six months to December 31, 2024 fell 1.4 percent to \$51.5 million, compared to the prior corresponding period (BD: Feb 28, 2024).

CLINUVEL: DILIGENS SALUD ARGENTINA SCENESSE DISTRIBUTOR

[CLINUVEL PHARMACEUTICALS](#)

Clinuvel says Buenos Aires' Diligens Salud SA will exclusively distribute its Scenesse, or afamelanotide, for erythropoietic protoporphyria in Argentina.

FDA CLINICAL HOLD FOR NEURIZON NUZ-001 ALS APPLICATION

[NEURIZON \(FORMERLY PHARMAUST\)](#)

Neurizon says the US Food and Drug Administration has put its investigational new drug application for NUZ-001 for amyotrophic lateral sclerosis (ALS) on "clinical hold". Neurizon said the FDA outlined it had "certain concerns about the sufficiency of information to assess the application and any risks to human subjects of the trial and with the proposed dosing regime".

IMMURON UNAUDITED H1 TRAVELAN SALES UP 70% TO \$4m

[IMMURON](#)

Immuron says unaudited sales of its Travelan gastro-intestinal immune supplement for the six months to December 31, 2024 were up 70 percent to \$4.0 million.

POWERHOUSE TAKES 7.4% OF PERCHERON

[PERCHERON THERAPEUTICS](#)

Brisbane's Powerhouse Ventures Ltd says it has increased its substantial shareholding in Percheron from 55,000,000 shares (5.058%) to 80,000,000 shares (7.36%).

PERENNIAL TAKES 13% OF MEDADVISOR

[MEDADVISOR](#)

Sydney's Perennial Value Management says it has increased its Medadvisor holding from 65,656,394 shares (11.91%) to 73,580,401 shares (13.33%)